Pharmacokinetics comparison of four major bioactive components in normal and blood stasis rats after administration of Naoxintong Capsule by UPLC-TQ/MS

Wei-Xia Li  
The First Affiliated Hospital of Henan University of Chinese Medicine

Pan-pan Chen  
The First Affiliated Hospital of Henan University of CM

Shuqi Zhang  
Henan University of Chinese Medicine

Man-man Li  
The First Affiliated Hospital of Henan University of CM

Hui Zhang  
The First Affiliated Hospital of Henan University of CM

Xiaoyan Wang  
The First Affiliated Hospital of Henan University of CM

Lu Niu  
The First Affiliated Hospital of Henan University of CM

Jinfang Tang (✉ a0519@163.com )

Xuelin Li  
The First Affiliated Hospital of Henan University of CM

Research

Keywords: Naoxintong capsules, acute blood stasis rat model, UPLC-TQ/MS, pharmacokinetics

DOI: https://doi.org/10.21203/rs.3.rs-23228/v1

License: ☑️ ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background Blood stasis is one major cause of cardiovascular and cerebrovascular diseases. Naoxintong capsule (NXTC), a Chinese patent medicine, has been widely employed in the prevention and treatment against cardiovascular and cerebrovascular diseases. However, the pharmacokinetics comparison of NXTC in normal and blood stasis rats were remain obscured.

Methods Acute blood stasis rats were induced by being placed in ice-cold water during the interval between two injections of adrenaline hydrochloride. Normal and blood stasis rats were administrated of NXTC suspension at the dosage of 5 g·kg⁻¹, and blood was collected at different time points after then. Concentrations of four main components including caffeic acid, ferulic acid, formononetin and tanshinone IIA in rat plasma were quantified by UPLC-TQ/MS. The pharmacokinetic parameters were calculated by Phoenix WinNonlin v6.2 software.

Results It was found that C max, AUC all, AUC INF_obs, Vz_F_obs and MRT last of ferulic acid, AUC all, Vz_F_obs and MRT last of caffeic acid in blood stasis rats were significantly different (P < 0.05) from normal rats. Compared with normal rats, C max of ferulic acid and formononetin decreased significantly in the plasma of acute blood stasis rats, AUC all of caffeic acid and ferulic acid decreased notably, AUC INF_obs of ferulic acid decreased remarkably, Vz_F_obs and MRT last of ferulic acid and caffeic acid increased reversely. It is suggested that the absorption of the four components of NXTC in acute blood stasis rats was weakened, and the elimination time was prolonged.

Conclusions The significant difference in some different parameters of the 4 NXTC components in normal and blood stasis rats might be caused by increasing of blood viscosity and slowing down of blood flow in acute blood stasis rats. The pharmacokinetic study under pathological condition provided important information for more rational use of NXTC in clinical situations.

Background

Naoxintong Capsule (NXTC), a Chinese patent medicine, is originated from a classic traditional Chinese prescription named Buyang Huanwu Decoction, which was recorded in the ancient medical book Yi-Lin-Gai-Cuo written by Qingren Wang in Qing Dynasty. It is composed of 16 traditional Chinese herbs (TCH), including 11 plant herbs Astragali Radix (Huangqi), Paeoniae Radix Rubra (Chishao), Salviae miltiorrhizae Radix et Rhizoma (Danshen), Angelicae Sinensis Radix (Danggui wei), Chuanxiong Rhizoma (Chuanxiong), Persicae Semen (Taoren), Carthami Flos (Honghua), Spatholobi Stem (Jixueteng), Achyranthis bidentatae Radix (Niuxi), Cinnamomi Ranulus (Guizhi), Mori Ramulus (Sangzhi), 2 resin herbs Olibanum (Ruxiang) and Myrrha (Moyao), and 3 animal herbs Pheretima (Dilong), Scorpio (Quanxie) and Hirudo (Shuizhi) [1]. NXTC is also one of commercial medicinal products approved by the China Food and Drug Administration and listed in the Chinese Pharmacopoeia 2015 with the effect of invigorating qi and activating blood circulation, removing blood stasis and dredging collaterals [2]. NXTC has gained the National Chinese Medicine Protection Certificate in 2014, and has been included in the
National Basic Drug List (2012 edition). Modern researches show that the pharmacological effects of NXTC mainly focus on improvement of blood rheology and blood coagulation function, anti-myocardial ischemia and ischemia/reperfusion injury, anti-atherosclerosis, anti-myocardial fibrosis, anti-cerebral I/R injury, improvement on learning and memory functions [3]. It is commonly used for the treatment of coronary heart disease, angina pectoris, stroke, secondary prevention of myocardial ischemia, cerebral infarction, transient ischemic attack, vertebro-basilar insufficiency, carotid atherosclerosis, and other cardiovascular and cerebrovascular diseases [4].

Promoting blood circulation and removing blood stasis is the basic pharmacological action of NXTC in the treatment of cardiovascular and cerebrovascular diseases [5]. The active chemical ingredients of NXTC mainly include flavonoids, flavonoid glycosides, phenanthraquinones, phenolic acids, terpenoids, and polysaccharide, which are related to the pharmacological functions of NXTC on inhibition of platelet aggregation, anti-inflammation, reduction of apoptosis and ROS production, activation of lipid metabolism, promotion of angiogenesis and lesion plaque stability, attenuation of vascular calcification [1, 6–9]. Many researchers have been trying to explore and identify the major and bioactive constituents of NXTC, and many chemical constituents in NXTC in vitro were quantified [10–12].

Nowadays, it is of great significance to study the pharmacokinetics and metabolism of TCH components for promoting its modernization. Therefore, some studies were conducted to explore the pharmacokinetics and metabolites of the main components of NXTC. A total of 36 prototype compounds and 52 metabolites of NXTC were identified or tentatively characterized in beagle dog urine and feces [13]; the pharmacokinetic profiles of caffeic acid, ferulic acid, formononetin, cryptotanshinone and tanshinone IIA in healthy rats have already been reported [14]. However, it is generally known that when the body is in pathological state, the pharmacokinetic process of compounds will change, and even has a significant difference with the normal state [15, 16].

Therefore, it is necessary to study the pharmacokinetic parameters changes in pathological state. In addition, the pharmacokinetic data obtained in pathological state will be more beneficial to clinical application than in normal state. Based on this, we employed the pharmacokinetics comparison of the main active components of NXTC between normal and blood stasis model rats, which will provide more valuable data for illuminating the variation mechanism of invigorating qi and activating blood circulation, removing blood stasis and dredging collaterals after oral administration of NXTC, and for better clinical applications of NXTC.

**Materials And Methods**

**Instrument**

Thermo TSQ Altis high performance liquid chromatography combined with triple quadrupole mass spectrometer (Thermo Company, USA), XS105 electronic balance (Mettler-Toledo Group), JA5003 electronic balance (Shanghai Shunyu Hengping Scientific Instrument Co. Ltd.), Neofuge 1600R desktop
cryogenic high-speed centrifuge (Shanghai Lishen Scientific Instruments Co. Ltd.), miVac Duo vacuum centrifuge concentrator (GeneVac Company, UK), VG 3 S25 vortexer (IKA Company of Germany); KQ-100DE digital ultrasonic cleaner (Kunshan Ultrasound Instrument Co., Ltd.); Elemental 18120 Molecular Ultra Pure Water System (Shanghai Moller Scientific Instrument Co., Ltd.).

Reagents And Materials

NXTCs (Shanxi Buchang Pharmaceutical Co., Ltd., batch number: 190193) and adrenaline hydrochloride injection (Suicheng Pharmaceutical Co., Ltd., specifications: 1mL: 1 mg, batch number: 61903011) both were purchased from pharmacy of the First Affiliated Hospital of Henan University of Chinese Medicine (Zhengzhou, China). Reference standards of caffeic acid, ferulic acid, stigmatin, tanshinone II A were purchased from Nanjing Liangwei Biological Technology Co., Ltd. with purity above 98% (Nanjing, China). Internal standards including clarithromycin and propione sulphonate were purchased from National Institutes for Food and Drug Control with purity above 98% (Beijing, China). Ultra-pure water was purified by Molecular waters purification system. Acetonitrile (HPLC grade) and methanol (HPLC grade) were purchased from Merck KGaA (Darmstadt, Germany). Formic acid (HPLC grade) was purchased from Dikma Technology Co., Ltd (Tianjin, China). Ultra-pure water was purified by using a Milli-Q system (Milford, MA, USA).

Ethical statement

Female Sprague–Dawley (SD) rats (6-8 weeks old, weighing 220 ± 20 g) were purchased by Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). Before the experiment, the rats were fed adaptively for one week, keeping the circadian rhythm for 12 hours and feeding and drinking freely. The temperature and humidity meet the requirements of animal feeding. Animal care and experimental protocols were performed based on 'Detailed Rules and Regulations for Administration and Implementation of Biomedical Animal Experiments' (No. 1998-55, Ministry of Public Health, China). The study protocol was approved by the Ethical Committee of the First Affiliated Hospital of Henan University of Chinese Medicine.

NXTC Solution Preparation

The content of NXTC was dispersed in 0.5% CMC-Na aqueous solution to produce the NXT suspension with the concentration of 0.33 g/mL.

Preparation of reference substance reserve solution, internal standard reserve solution and quality control sample

Caffeic acid, ferulic acid, anthocyanin and tanshinone II A were weighed accurately and then serially dissolved in methanol to obtain the reference stock solutions with different concentrations of 30.5, 30, 38...
and 21.5 mg/mL respectively. Six series of mixed reference solutions were gained with appropriate
individual reference stock solution mixed and diluted with methanol in volumetric flask: 0.5, 1, 5, 10, 50
and 100 ng/mL caffeic acid, 1, 5, 10, 50, 100 and 500 ng/mL ferulic acid, 0.05, 0.1, 0.5, 1, 5 and 10 ng/mL
anthocyanin and 0.5, 1, 5, 10, 50 and 100 ng/mL tanshinone II A.

As internal standard substances, clarithromycin and probenecid were weighed precisely and dissolved
with methanol to obtain the internal standard reserve solutions with concentrations of 532 and 536
mg/mL respectively. Appropriate amount of internal standard reserve solutions was diluted with
methanol to provide the mixed internal standard reserve solution with clarithromycin of 106.4 ng/mL and
probenecid of 107.2 ng/mL.

Quality control (QC) samples of caffeic acid with concentrations of 30, 50, 500 ng/mL, ferulic acid with
concentrations of 10, 20, 200 ng/mL, anthocyanin with concentrations of 0.5, 1, 10 ng/mL and
tanshinone II A with concentrations of 1, 5, 50 ng/mL were prepared with blank plasma.

**Chromatography and mass spectrometry conditions**

Liquid chromatographic analysis and mass spectrometry detection was performed on Thermo Scientific™
TSQ Altis™ (Thermo Company, USA). Chromatographic separation was carried out on an Acquity UPLC
BEH C18 column (2.1 ´ 100 mm, 1.7 μm) maintained at 30°C. The mobile phase gradient conditions
consisted of 0.1% aqueous formic acid (A) and methanol (B): 0–2 min, 40–100% B; 2–5 min, 100% B; at
5–5.1 min, 100–40% B; 5.1–8 min, 40% B. The flow rate was 0.2 mL/min. The autosampler was
conditioned at 10 °C and the sample injection volume was 1 μL.

The ESI source was set in both positive and negative ionization mode. The parameters in the source were
set in the following manner: positive ion scanning voltage, 3500 V; negative ion scanning voltage, 2500 V;
sheath gas velocity, 25 arb; auxiliary air velocity, 7 arb; collision gas pressure, 1.5 mTorr; ion transmission
tube temperature, 325 °C; ion source temperature, 400 °C. The scanning mode was set multiple reaction
monitoring (MRM) mode and the selected monitor ion were \( m/z \) 178.96®135.04 for caffeic acid, \( m/z \)
192.95®134.00 for ferulic acid, \( m/z \) 267.00®251.97 for anthocyanin, \( m/z \) 295.05®277.20 for tanshinone
II A, \( m/z \) 748.35®590.29 for clarithromycin, and \( m/z \) 284.00®240.05 for propafenone. The collision
energy and RF-lens were optimized for precursor/product ion pairs of each analyte and the selected
values are presented in Table 1.

**Modeling, drug administration and preparation of plasma samples**

In this experiment, twenty rats were randomly divided into blank administration group and model
administration group with 10 rats in each group respectively. After 7 days of acclimation, the rats in the
model administration group were given adrenaline hydrochloride injection (0.8 mg/kg) subcutaneously.
After 2 h, the rats were placed in 0°C ~ 2°C ice water to swim for 4 minutes, the first time 4 hours after the administration of epinephrine hydrochloride injection, subcutaneous injection of epinephrine hydrochloride injection 0.8 mg/kg was performed again, resulting in a model of acute blood stasis in rats. All rats fasted for 12 hours and drank freely. NXTC suspension was administrated by gavage at a dose of 5g/kg. At 0.083, 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10 and 12 hours after administration, blood samples were collected from the eye orbital venous plexus of rats and placed in a heparinized centrifuge tube. Plasma was separated by 3000 r/min centrifugation for 10 min and stored at -80 °C for determination.

**Plasma Sample Preparation**

100 mL of plasma sample was precisely pipetted and 20 mL of 10% formic acid water, 10 mL of internal standard solution were added, the mixture was vortexed for 3 min, then 300 mL of methanol was added and vortexed for 5 min additionally. Subsequently, the sample was centrifugated at 14 000 r/min for 10 min. The supernatant was centrifugally concentrated to dryness under vacuum condition. The residue was re-dissolved in 100 mL methanol, agitated on a vortexer for 3 min and centrifugated at 14000 r/min for 10 min, then the supernatant was obtained for analysis.

**Methodological Investigation**

*Specificity*

The blank plasma of rats, blank plasma of rats added with reference solution and internal standard solution, and the plasma samples obtained from rats of model group were taken 100 mL respectively, the samples were processed applying the sample processing procedure in item 2.5. The ion chromatograms of the ingredients were acquired abiding by the corresponding chromatographic and mass spectrometric methods in item 2.3.

*Linearity, limit of detection (LOD) and lower limit of quantification (LLOQ)*

Six duplicates of 100 mL blank rat plasma were added with a series of mixed reference solutions with different concentrations. The samples were processed according to the sample processing procedure in item 2.5 and conducted LC-MS/MS analysis. Taking the concentration of each substance to be measured as the abscissa (x), the ratio of the peak area of the substance against the internal standard as the ordinate (y), and the reciprocal of the concentration (1/x) as the weighting coefficient for linear regression, the regression equations of the calibration curves of each ingredient in rat plasma were established. By comparing the results of samples with known analyte concentration and those of blank samples, the signal-to-noise ratio (S/N) of 3:1 was determined to be the LOD, the S/N of 10:1 was determined to be the LLOQ, which is the lowest concentration point of the standard curve.

*Precision and accuracy*
Certain duplicates of 100 mL blank plasma were respectively added with different concentrations of mixed reference solution and internal standard solution to prepare the lower limit of quantification sample and quality control samples with low, medium and high concentrations. Six samples were prepared in parallel with each concentration, which were processed according to the procedure displayed in item 2.5. The measured concentration of QC sample was calculated according to the accompanying standard curve. Measurements for 3 consecutive days were implemented to investigate the accuracy and precision of the established analysis method.

**Recovery of extraction and matrix effect**

Quality control samples of low, medium and high concentrations prepared from 100 mL blank plasma were processed according to the sample processing method above. The peak area of each component was recorded as A1. Other duplicates of 100 mL blank plasma were also processed according to the method above. The residues were respectively re-dissolved in reference solutions of low, medium and high concentration containing internal standard. The peak area of each component was recorded as A2. The low, medium and high concentration reference solutions containing internal standard were also respectively injected into the analysis system. The peak area of each component was recorded as A3 here. Each sample was prepared in 6 duplicates. The recovery (%) was the ratio of A1 to A3, and the matrix effect (%) was the ratio of A2 to A3.

**Stability**

The quality control samples with low, medium and high concentration were prepared and placed at 4 °C for 0, 2, 4, 8, 12 and 24 h for analysis. The quality control samples were also frozen at -80 °C and thawed at room temperature for 3 cycles with 6 duplicates for each concentration respectively. According to the established calibration curve, the measured concentration of QC sample was calculated, and compared with the labeled concentration to investigate the stability of each component in rat plasma.

**Data processing and analysis**

The data collection and sample analysis were controlled by Tracefinder 4.1 software and the data were processed with Microsoft Excel. The content of each compound was expressed as $x \pm s$. The obtained data of content were processed with Phoenix Winnonlin (version 6.2, Pharsight Corporation, USA) pharmacokinetic software, and the pharmacokinetic parameters were calculated applying non-compartment model.

**Results**

**Contents of four components in Naoxintong Capsule**
The LC-MS/MS analysis of the sample solution revealed that the contents of caffeic acid, ferulic acid, anthocyanin and tanshinone IIA in Naoxintong capsule were determined as 0.011, 0.099, 0.060 and 0.148 mg×g$^{-1}$ respectively. The chemical structure formulas of the four compounds are shown in Figure 1.

**Methodological investigation**

*Specificity test*

The endogenous substances in blank plasma did not interfere with the determination of caffeic acid, ferulic acid, anthocyanin, tanshinone IIA, clarithromycin and probenecid. The extracted ion flow chromatograms of each component are shown in Figure 2.

*Linearity, LOD and LLOQ*

The calibration curve and lower limit of quantification of the four components are displayed in Table 2. The linearity of each component is good within the corresponding concentration range, and the correlation coefficient is greater than 0.99, meeting the requirements of in vivo drug analysis method.

*Precision and accuracy*

Three QC samples of different mass concentrations with six duplicates for each were analyzed for three consecutive days. The results showed that the RSD of intra-day precision, intra-day precision and accuracy of each sample could meet the requirements (Table 3).

*Recovery and matrix effect*

The results of matrix effect and extraction recovery of each component could meet the requirements of biological sample detection (Table 4).

*Stability*

The stability of the plasma sample is good after 24 hours of cold storage (4 °C) or 3 cycles of freeze-thaw (Table 5).

**Comparative analysis of blood concentration-time curves for four blood components**

The blood concentration-time curves of caffeic acid, ferulic acid, formononetin and tanshinone IIA in NXTC in normal and acute blood stasis model rats are shown in Figure 3.

**Comparative analysis of pharmacokinetic parameters**
The statistical analysis results of main pharmacokinetic parameters of caffeic acid, ferulic acid, formononetin and tanshinone IIA in normal and acute blood stasis model rats intragastrically administrated with NXTC are shown in Table 6. As the pharmacokinetic parameters of caffeic acid, ferulic acid, formononetin and tanshinone IIA exhibited above, the peak time \( T_{\text{max}} \) of the four components was 0.12 ± 0.05, 0.11 ± 0.04, 0.08 ± 0.00 and 0.13 ± 0.05 h, respectively, which indicated that the above four components could be absorbed into the blood rapidly. Concluded from the results of AUC\(_{\text{all}}\) and AUC\(_{\text{INF,obs}}\) and the peak concentrations \( C_{\text{max}} \) of the four components being 5.01±0.74, 71.37±15.56, 5.70±1.19 and 2.08±0.57 mg/L, ferulic acid was absorbed best in body of normal rats, with \( C_{\text{max}} \) being 12-35 times of the other three components. Tanshinone IIA exhibited the lowest \( C_{\text{max}} \), indicating that its absorption being worse than the other three components. However, the apparent distribution volume (VZ\(_{\text{F,obs}}\)) and clearance rate (CL\(_{\text{F,obs}}\)) of caffeic acid and ferulic acid were smaller than those of formononetin. With the largest VZ\(_{\text{F,obs}}\) and CL\(_{\text{F,obs}}\), tanshinone IIA possessed a widespread in vivo distribution. The average retention time of four components was 4.40 ± 0.46 ~ 5.78 ± 0.29 h.

**Discussion**

In this experiment, compared with the normal group, the \( T_{\text{max}} \) of the four components of NXTC were prolonged in acute blood stasis model rats with no statistical difference and the \( C_{\text{max}} \) of the four components were decreased, with the decrease of ferulic acid and formononetin being statistically significant \( (P < 0.05)\), which suggested that the blood circulation disorder caused by acute blood stasis hindered the absorption of the four components. The AUC\(_{\text{all}}\) of caffeic acid and ferulic acid were significantly reduced \( (P < 0.05)\) in model group. The AUC\(_{\text{INF,obs}}\) of ferulic acid was also remarkable reduced \( (P < 0.01)\). It was observed that compared with the normal group, the clearance rate of tanshinone IIA in the model group was reduced, which allowed more tanshinone IIA to remain in rats body and play its role in the treatment of blood stasis. Significant elevations of the plasma concentration of ferulic acid and caffeic acid \( (P < 0.05)\) and increased in the mean retention time (MRT\(_{\text{last}}\)) of caffeic acid and ferulic acid \( (P < 0.05)\) increased as well. The difference of the above results might be due to the characteristics of "viscosity, concentration, coagulation and aggregation" of the blood in acute blood stasis model rats, which makes the blood viscosity increase, the blood flow slow down, the absorption of components slow down, \( T_{\text{max}} \) and MRT\(_{\text{last}}\) prolonged.

Blood stasis syndrome is a pathological state of blood circulation, which is described as slow or accumulation of blood due to xinqi disorder in traditional Chinese medicine (TCM) and TCM believes that the "sadness" of seven emotions (qiqing) and the "cold evil" of six evils (liuxie) are the main causes of acute blood stasis [17]. Now blood stasis is usually understood as a blood system disease, pathological studies show that blood stasis is mainly characterized by cardiovascular and cerebrovascular diseases, such as cerebral infarction, myocardial infarction, coronary heart disease, hypertension and so on [17-19]. The efficacy of NXTC capsule is replenishing qi and activating blood, removing blood stasis and dredging collaterals. It is often used in the treatment of cardiovascular and cerebrovascular diseases, which is closely related to its main components caffeic acid, ferulic acid, formononetin and tanshinone IIA.
Numerous studies have demonstrated that caffeic acid and its derivatives have pharmacological effects such as antioxidation, immune regulation, anti-cancer, regulation of cardiovascular and cerebrovascular diseases and protection of brain tissue damage [20-22]. Ferulic acid is a metabolite of caffeic acid methylation, which can promote bone marrow hematopoiesis, enhance immunosuppression, protect cardiovascular system, reduce blood lipid, resist arteriosclerosis and inhibit platelet aggregation [23-25]. Formononetin has pharmacological actions on improving atherosclerosis and inhibiting the proliferation of vascular smooth muscle cells [26, 27]. In recent years, tanshinone IIA has attracted the attention of much more researchers in cardiovascular and cerebrovascular aspects. The protective effects of tanshinone IIA on the heart include preventing the formation of atherosclerosis, preventing myocardial injury and hypertrophy, expanding coronary arteries and related mechanisms of action have been reported [28-31].

In the pathological state, the pharmacokinetic of drug is different from the normal state due to changes in the physiological state and biochemical response of the body. Given that NXTC is usually used for the treatment of patients with blood stasis, we studied the pharmacokinetics of NXTC in rats with acute blood stasis. The acute state of blood stasis may be caused by abnormal hemorheology, such as the increase of blood viscosity and coagulation degree, blood aggregation, vascular obstruction and so on [32, 33]. In the model group, it can be observed from the overall point of view that the $T_{\text{max}}$ and $C_{\text{max}}$ of the four components were prolonged and decreased, respectively, parameters of $\text{AUC}_{\text{all}}, V_{z\_F\_obs}$ and $\text{MRT}_{\text{last}}$ were changed as well, indicting that the absorption and metabolism of NXTC were affected in acute blood stasis. These results provide important information for guiding the clinical rational use of drugs.

**Conclusion**

Herein, we have established the analytical method to probe the pharmacokinetic properties of the four main ingredients caffeic acid, ferulic acid, formononetin and tanshinone IIA of NXTC in acute blood stasis rats compared with the corresponding profile in normal rats. The parameters demonstrated that the $C_{\text{max}}$ of ferulic acid and formononetin decreased statistically significantly, the $\text{AUC}_{\text{all}}/\text{AUC}_{\text{INF\_obs}}$ of ferulic acid and the $\text{AUC}_{\text{all}}$ of caffeic acid were all significantly reduced. The plasma concentration and mean retention time (MRT$_{\text{last}}$) of ferulic acid and caffeic acid all increased. The alteration of the pharmacokinetics was consistent with the change of the rheological characteristics of the blood in acute blood stasis rats. These investigations may provide experimental basis for the plan adjustment of clinical medication of NXTC for patients with blood stasis.

**Abbreviations**

NXTC: Naoxintong Capsule; QC: quality control; ESI: electrospray ion source; MRM: multi response monitoring; IS: internal standard; LOD: limit of detection; LLOQ: lower limit of quantification; S/N: signal-to-noise ratio.
to-noise; Cmax: peak concentrations; Tmax: peak time; VZ_F_obs: apparent distribution volume; CL_F_obs: clearance rate; MRTLast: the mean retention time.

**Declarations**

**Acknowledgements**

Not applicable.

**Authors’ contributions**

WXL and PPC contributed equally to this work. JFT and XLL conceived and designed the study. HZ was mainly responsible for the instrument operation. WXL and SQZ conducted the data analysis and wrote the manuscript. PPC and MML revised the manuscript. XYW and LN conducted the animal experiment. CXL provided the advice for the study. All authors read and approved the final manuscript.

**Funding**

This work was supported by the National Science and Technology Major Project of China “Key New Drug Creation and Manufacturing Program” (grant No. 2015ZX09501004-001-007).

**Ethics approval and consent to participate**

Animal care and experimental protocols were performed based on ‘Detailed Rules and Regulations for Administration and Implementation of Biomedical Animal Experiments’ (No. 1998-55, Ministry of Public Health, China). All experiments involving animals were approved by the Animal Experimental Ethics Committee of the First Affiliated Hospital of Henan University of Chinese Medicine.

**Consent for publication**

All of authors consent to publication of this study in journal of Chinese Medicine.

**Author details**
1 Henan Province Engineering Laboratory for Clinical Evaluation Technology of Chinese Medicine, the First Affiliated Hospital of Henan University of Chinese Medicine, No. 19, Renmin Road, Jinshui District, Zhengzhou 450008, China. 2 Department of Pharmacy, Henan University of Chinese Medicine, No. 156, Jinshui East Road, Zhengdong New District, Zhengzhou 450046, China. 3 Engineering Research Center for Modernization of clinical application of Chinese Herbal Pieces in Henan Province, No. 19, Renmin Road, Jinshui District, Zhengzhou 450008, China. 4 Provincial and ministerial co construction Collaborative Innovation Center for Prevention and treatment of respiratory diseases with traditional Chinese Medicine of Henan University of Chinese Medicine, No. 156, Jinshui East Road, Zhengdong New District, Zhengzhou 450046, China.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

References
1. Wang H, Qiu LZ, Ma YK, Zhang LS, Chen L, Li CX, Geng X, You XY, Gao XM. Naoxintong inhibits myocardial infarction injury by VEGF/eNOS signaling-mediated neovascularization. J Ethnopharmacol. 2017;209:13–23.
2. Chinese Pharmacopoeia commission. Pharmacopoeia of the People's Republic of China. Beijing: China Medical Science Press; 2015. pp. 1379–80.
3. Group of Chinese Experts Consensus on Clinical Application of Naoxintong Capsule. Chinese Experts Consensus on Clinical Application of Naoxintong Capsule. Chin. J. Integr. Med. 2018;24;232-6.
4. Han JH, Tan H, Duan YJ, Chen YL, Zhu Y, Zhao BC, Wang Y, Yang XX. The cardioprotective properties and the involved mechanisms of NaoXinTong Capsule. Pharmacol. Res. 2019;141;409 – 17.
5. Li WX, Zhang SQ, Zhao YD, Tang JF, Li CX, Wang XY, et al. Study progress on chemical compounds, pharmacological action and clinical application of Naoxintong capsule. China J Chin Mat Med. 2018;43:1998–2005.
6. Lv JZ, Xiong W, Lei TT, Wang HL, Sun MH, Hao EW, Wang ZP, Huang XQ, Deng SP, Deng JG, Wang Y. Amygdalin ameliorates the progression of atherosclerosis in LDL receptor deficient mice. Mol Med Rep. 2017;16:8171–9.
7. Wang J, Xiong XJ, Feng B. Cardiovascular effects of salvianolic acid B. Evid Complement Alternat Med. 2013. Doi:.
8. Choi ES, Yoon JJ, Han BH, Jeong DH, Lee YJ, Kang DG, Lee HS. Ligustilide attenuates vascular inflammation and activates Nrf2/HO-1 induction and, NO synthesis in HUVECs. Phytomedicine. 2018; 38;12–23.

9. Jin L, Piao ZH, Sun S, Liu B, Kim GR, Seok YM, Lin MQ, Ryu Y, Choi SY, Kee HJ, Jeong MH. Gallic acid reduces blood pressure and attenuates oxidative stress and cardiac hypertrophy in spontaneously hypertensive rats. Sci. Rep. 2017;7;15607.

10. Wang HL, Jiang Y, Ding MY, Li J, Hao J, He J, Wang H, Gao XM, Chang YX. Simultaneous determination and qualitative analysis of six types of components in Naoxintong capsule by miniaturized matrix solid-phase dispersion extraction coupled with ultra high-performance liquid chromatography with photodiode array detection and quadrupole time-of-flight mass spectrometry. J. Sep. Sci. 2018;41;2064-84.

11. Wang SS, Xu HY, Ma Y, Wang XG, Shi Y, Huang B, Tang SH, Zhang Y, Li DF, Liang RX, Yang HJ. Characterization and rapid identification of chemical constituents of Naoxintong capsules by UHPLC-linear ion trap/Orbitrap mass spectrometry. J. Pharm. Biomed. Anal. 2015;111;104 – 18.

12. Ma X, Lv B, Li P, Jiang X, Zhou Q, Wang X, Gao X. Identification of “multiple components-multiple targets-multiple pathways” associated with Naoxintong Capsule in the treatment of heart diseases using UPLC/Q-TOF-MS and network pharmacology. Evid Based Compl Alt. 2016. Doi:.

13. He Y, Su WW, Chen TB, Zeng X, Yan ZH, Guo JM, Yang W, Wu H. Identification of prototype compounds and derived metabolites of naxintong capsule in beagle dog urine and feces by UFLC-Q-TOF-MS/MS. J. Pharm. Biomed. Anal. 2019;176;112806.

14. Li J, Bai Y, Bai Y, Zhu R, Liu W, Cao J, An M, Tan Z, Chang YX. Pharmacokinetics of caffeic Acid, ferulic Acid, formononetin, cryptotanshinone, and tanshinone IIA after oral administration of Naoxintong Capsule in rat by HPLC-MS/MS. Evid. Based Complement Alternat Med. 2017. Doi:.

15. Pfeiffers S. The effect of disease on the pharmacokinetics of drugs. 3. Cardiovascular, respiratory, neoplastic, thyroid diseases, diabetes, infections, mucoviscidosis, obesity, operations, burns etc. Pharmazie. 1991;46:830–9.

16. Ru Y, Yang Y, Chen Y. Pharmacokinetics of Chinese medicines: strategies and perspectives. Chin. Med. 2018;13;4.

17. Chiu CC, Lan CY, Chang YH. Objective assessment of blood stasis using computerized inspection of sublingual veins. Comput Meth Prog Bio. 2002;69:1–12.

18. Chiu M, Chen KJ, Yin HJ. Relationship between platelet activation related factors and polymorphism of related genes in patients with coronary heart disease of blood-stasis syndrome. Chin J Integr Med. 2008;14:267–73.

19. Yue SJ, Xin LT, Fan YC, Li SJ, Tang YP, Duan JA, Guan HS, Wang CY. Herb pair Danggui-Honghua: mechanisms underlying blood stasis syndrome by system pharmacology approach. Sci Rep. 2017;11(7);:1–15.

20. Li HX, Han SY, Wang XW, Ma X, Zhang K, Wang L, Ma ZZ, Tu PF. Effect of the carthamins yellow from Carthamus tinctorius L. on hemorheological disorders of blood stasis in rats. Food Chem Toxicol.
21. CL YKW, WJZ, W JT FJZ. Results of Different Quantitative Diagnosis Analysis on the Symptoms and Signs of Blood Stasis Syndrome in Coronary Heart Disease. World Sci Technol. 2009;11:684–8.

22. Tsai SJ, Chao CY, Yin MC. Preventive and therapeutic effects of caffeic acid against inflammatory injury in striatum of MPTP-treated mice. Eur J Pharmacol. 2011;670:441–7.

23. Anwar J, Spanevello RM, Thom G, et al. Effects of caffeic acid on behavioral parameters and on the activity of acetyl-cholinesterase in different tissues from adult rats. Pharmacol Biochem Behav. 2012;103:386–94.

24. Kumaran KS, Prince PS. Caffeic acid protects rat heart mi-tochondria against isoproterenol-induced oxidative damage. Cell Stress Chaperon. 2010;15:791–806.

25. Colombo R, Papetti A. An outlook on the role of decaffeinated coffee in neurodegenerative diseases. Crit Rev Food Sci Nutr. 2020;60:1–20.

26. Chaudhary A, Jaswal VS, Choudhary S, Sharma A, Beniwal V, Tuli HS, Sharma S. Ferulic Acid: A Promising Therapeutic Phytochemical and Recent Patents Advances. Recent Pat Inflamm Allergy Drug Discov. 2019;13:1–9.

27. Li Y, Cao SY, Lin SJ, Zhang JR, Gan RY, Li HB. Polyphenolic Profile and Antioxidant Capacity of Extracts From Gordonia axillaris Fruits. Antioxidants. 2019;8:1–14.

28. Zhang X, Wang Q, Wang X, Chen X, Shao M, Zhang Q, Guo D, Wu Y, Li C, Wang W, Wang Y. Tanshinone IIA protects against heart failure post-myocardial infarction via AMPKs/mTOR-dependent autophagy pathway. Biomed Pharmacother. 2019;112:1–9.

29. Wang H, Zhong L, Mi S, Song N, Zhang W, Zhong M. Tanshinone IIA prevents platelet activation and down-regulates CD36 and MKK4/JNK2 signaling pathway. MC Cardiovasc Disord. 2020;20:1–7.

30. Lu J, Shan J, Liu N, Ding Y, Wang P. Tanshinone IIA. Can Inhibit Angiotensin II-Induced Proliferation and Autophagy of Vascular Smooth Muscle Cells via Regulating the MAPK Signaling Pathway. Biol Pharm Bull. 2019. . 42;Doi:.

31. Song T, Yao Y, Wang T, Huang H, Xia H. Tanshinone IIA ameliorates apoptosis of myocardiocytes by up-regulation of miR-133 and suppression of Caspase-9. Eur J Pharmacol. 2017;15:1–30.

32. Braun H, Bueche CZ, Garz C, Oldag A, Heinze HJ, Goertler M, Reymann KG, Schreiber S. Stases are associated with blood-brain barrier damage and a restricted activation of coagulation in SHRSP. J Neurol Sci. 2012;322:71–6.

33. Chiu CC, Lan CY, Chang YH. Objective assessment of blood stasis using computerized inspection of sublingual veins. Comput Meth Prog Bio. 2002;69:1–12.

Tables
Table 1
Collision Energy and Ion Lens Voltage Detection Parameters of Four Main Components and Internal Standard Compounds in Naoxintong Capsules

| compound        | [M + H]^+ (M/Z) | [M-H]^- (M/Z) | Parent ion→daughter ion | Collision energy(eV) | RF-lens(V) |
|-----------------|-----------------|---------------|--------------------------|----------------------|------------|
| caffeic acid    | 178.96          | 178.96→135. 04 |                         | 15.88                | 49         |
| ferulic acid    | 192.95          | 192.95→134. 00 |                         | 14.7                 | 44         |
| formononetin    | 267.00          | 267.00→251. 97 |                         | 20.27                | 68         |
| tanshinone IIA  | 295.05          | 295.05→277. 20 |                         | 19.78                | 67         |
| clarithromycin (IS) | 748.35        | 748.35→590. 29 |                         | 17.7                 | 74         |
| Probenecid (IS) | 284.00          | 284.00→240. 05 |                         | 14.97                | 57         |

Table 2
Calibration curve and quantitative LLOQ for four components in NXTC.

| component        | calibration curve | R      | linear range /ng·ml⁻¹ | LOD/ ng·ml⁻¹ | LLOQ/ng·ml⁻¹ |
|------------------|-------------------|--------|------------------------|--------------|--------------|
| caffeic acid     | \[Y = 3.195 \cdot 10^{-3} X + 2.034 \cdot 10^{-3}\] | 0.9995 | 0.5–100               | 0.1          | 0.5          |
| ferulic acid     | \[Y = 2.136 \cdot 10^{-4} X + 2.514 \cdot 10^{-5}\] | 0.9979 | 1–500                 | 0.5          | 1            |
| formononetin     | \[Y = 4.326 \cdot 10^{-3} X + 1.843 \cdot 10^{-3}\] | 0.9992 | 0.05–10               | 0.01         | 0.05         |
| tanshinone IIA   | \[Y = 4.102 \cdot 10^{-2} X - 8.833 \cdot 10^{-3}\] | 0.9994 | 0.5–100               | 0.1          | 0.5          |
Table 3
Precision and accuracy of the analysis method for four components in NXTC.

| component          | concentration of reference compound solution (ng/mL) | intraday content (ng/mL) | RR% | RSD% | interday content (ng/mL) | RR% | RSD% |
|-------------------|-----------------------------------------------------|--------------------------|-----|------|--------------------------|-----|------|
| caffeic acid      | 30                                                  | 30.42±1.61               | 101.40±5.73 | 5.31 | 31.77±1.12               | 105.90±3.73 | 3.54 |
|                   | 50                                                  | 55.73±6.06               | 111.46±1.21 | 10.88 | 52.24±4.35               | 104.48±8.70 | 8.31 |
|                   | 500                                                 | 496.61±7.80              | 99.32±7.56 | 7.61 | 480.47±2.34              | 96.09±4.65 | 4.84 |
| ferulic acid      | 10                                                  | 9.49±0.46                | 94.90±4.60 | 4.86 | 9.68±0.27                | 96.80±2.70 | 2.76 |
|                   | 20                                                  | 25.91±1.98               | 129.55±9.90 | 7.64 | 23.00±2.11               | 115.00±1.05 | 9.16 |
|                   | 200                                                 | 197.66±4.03              | 98.83±7.01 | 7.10 | 211.76±1.69              | 105.88±8.48 | 8.00 |
| formononetin      | 0.5                                                 | 0.55±0.07                | 110.00±1.40 | 12.08 | 0.58±0.05                | 116.00±1.86 | 8.66 |
|                   | 1                                                  | 1.14±0.12                | 114.00±1.20 | 10.13 | 1.17±0.06                | 117.00±6.00 | 4.91 |
|                   | 10                                                 | 11.04±1.57               | 110.40±1.57 | 1.24 | 10.95±0.48               | 109.50±1.09 | 4.35 |
| tanshine IIA      | 1                                                  | 1.46±0.20                | 146.00±2.00 | 13.95 | 2.11±0.56                | 211.00±6.09 | 26.32 |
|                   | 5                                                  | 4.59±0.53                | 91.80±10.60 | 11.51 | 4.84±0.44                | 96.80±8.80 | 9.13 |
|                   | 50                                                 | 55.61±3.93               | 111.22±7.86 | 7.07 | 56.62±7.46               | 113.24±1.49 | 13.17 |
Table 4
Recovery rate and matrix effect of the analysis method for four components in NXTC.

| component      | concentration of reference compound solution (ng/mL) | recovery rate (%) | RSD (%) | matrix effect (%) | RSD (%) |
|----------------|-------------------------------------------------------|-------------------|---------|-------------------|---------|
| caffeic acid   | 30                                                     | 81.90 ± 6.75      | 9.21    | 72.00 ± 3.97      | 6.19    |
|                | 50                                                     | 74.84 ± 6.27      | 9.37    | 119.00 ± 4.32     | 4.06    |
|                | 500                                                    | 69.09 ± 8.96      | 10.01   | 71.81 ± 7.20      | 12.27   |
| ferulic acid   | 10                                                     | 97.20 ± 13.85     | 15.94   | 100.39 ± 10.58    | 12.17   |
|                | 20                                                     | 83.76 ± 5.25      | 7.01    | 118.25 ± 6.22     | 5.88    |
|                | 200                                                    | 83.97 ± 4.86      | 6.47    | 96.15 ± 3.18      | 4.05    |
| formononetin   | 0.5                                                    | 78.56 ± 4.81      | 6.84    | 116.10 ± 15.39    | 14.82   |
|                | 1                                                      | 89.35 ± 11.61     | 14.52   | 110.34 ± 10.98    | 11.12   |
|                | 10                                                     | 71.24 ± 1.87      | 2.93    | 90.31 ± 9.32      | 11.30   |
| tanshinone IIA | 1                                                      | 22.01 ± 1.97      | 10.33   | 52.08 ± 4.70      | 10.09   |
|                | 5                                                      | 35.56 ± 1.43      | 4.49    | 45.55 ± 3.64      | 8.94    |
|                | 50                                                     | 30.10 ± 2.01      | 7.48    | 37.17 ± 4.15      | 13.67   |
Table 5
Investigation of the stability for four components in NXTC.

| component       | concentration of reference compound solution (ng/mL) | short term |        |        |
|-----------------|----------------------------------------------------|------------|--------|--------|
|                 |                                                    | content (ng/mL) | RSD %  | content (ng/mL) | RSD %  |
| cafefic acid    | 30                                                 | 36.73 ± 5.51 | 15.00  | 8.34 ± 0.56     | 8.25   |
|                 | 50                                                 | 52.11 ± 3.56 | 6.83   | 23.62 ± 1.14    | 5.29   |
|                 | 500                                                | 498.57 ± 40.88 | 8.20   | 255.89 ± 23.64  | 10.33  |
| ferulic acid    | 10                                                 | 11.79 ± 0.90 | 7.65   | 9.89 ± 0.85     | 9.40   |
|                 | 20                                                 | 21.38 ± 1.03 | 4.81   | 25.91 ± 1.81    | 7.64   |
|                 | 200                                                | 226.27 ± 7.07 | 3.12   | 197.66 ± 12.81  | 7.10   |
| formononetin    | 0.5                                                | 0.62 ± 0.03  | 5.54   | 0.55 ± 0.06     | 12.08  |
|                 | 1                                                  | 1.23 ± 0.06  | 4.93   | 1.14 ± 0.11     | 10.13  |
|                 | 10                                                 | 11.48 ± 0.31 | 2.67   | 11.04 ± 1.44    | 14.24  |
| tanshinone IIA  | 1                                                  | 1.81 ± 0.07  | 3.74   | 1.48 ± 0.18     | 13.05  |
|                 | 5                                                  | 4.78 ± 0.38  | 7.99   | 1.92 ± 0.20     | 11.51  |
|                 | 50                                                 | 53.49 ± 2.24 | 4.19   | 21.04 ± 3.43    | 18.22  |
Table 6
Pharmacokinetic parameters of four components in NXTC applying non-compartment model in normal and acute blood stasis model rats.

| Component      | n   | Rsq_adjusted | HL_Lambda_z | T_max | C_max | AUC_all | AUC_INF_obs | Vz_F_obs | Cl_F_obs | MRT_last |
|----------------|-----|--------------|-------------|-------|-------|---------|-------------|----------|----------|----------|
| Caffeic acid   | 7   | 0.77±0.12    | 5.15±1.01   | 0.12±0.05 | 5.01±0.74 | 18.9±1.98 | 22.8±3.40 | 18.1±3.23 | 2.27±0.73 | 4.69±0.39 |
|                | 6   | 0.54±0.10*   | 11.1±9.43   | 0.18±0.08 | 4.91±1.20 | 14.7±2.32 | 30.7±10.0 | 28.2±7.89 | 2.29±1.22 | 5.38±0.43* |
| Ferulic acid   | 7   | 0.78±0.08    | 5.29±1.42   | 0.11±0.04 | 71.3±15.5 | 160.±33.4 | 217.±44.3 | 23.1±1.69 | 3.22±0.46 |
|                | 6   | 0.52±0.34    | 6.11±0.54   | 0.12±0.05 | 30.8±19.5 | 63.4±16.6 | 96.4±18.4 | 46.8±1.00 | 4.95±0.85* |
| Formononetin   | 7   | 0.86±0.21    | 9.96±4.21   | 0.08±0.00 | 5.70±1.19 | 15.1±4.69 | 24.1±7.98 | 115.±41.7 | 13.6±4.54 |
|                | 6   | 0.76±0.11    | 5.03±2.62   | 0.37±0.35 | 3.82±0.84* | 11.8±1.41 | 18.0±6.97 | 132.±45.9 | 14.6±4.39 |
| Tanshinone IIA | 7   | 0.72±0.21    | 7.17±5.71   | 0.13±0.05 | 2.08±0.57 | 8.55±1.14 | 11.4±2.75 | 442.±123.76 | 56.7±21.1 |

Footnote: Rsq_adjusted represented a parameter to predict the fitting effect with the actual value, same as adjustment \( r^2 \); HL_Lambda_z represented elimination phase half-life; \( T_{\text{max}} \) represented time to peak; \( C_{\text{max}} \) represented peak concentration; \( AUC_{\text{all}} \) represented AUC spanned from the beginning of administration to the last point; \( AUC_{\text{INF}_\text{obs}} \) represented AUC spanned from the beginning of administration to the infinite time by extrapolation; \( Vz_{\text{F}_\text{obs}} \) represented apparent distribution volum; \( Cl_{\text{F}_\text{obs}} \) represented clearance rate; \( MRT_{\text{last}} \) represented average residence time. Compared with the normal group, * \( P < 0.05 \); ** \( P < 0.01 \).
| mod | 6   | ± 0.34 | ± 19.6 | ± 0.50 | ± 1.67 | ± 9.68 | ± 27.7 | ± 530. | ± 37.3 | ± 5.79 |
|-----|-----|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| el  | ± 3 | ± 18.6 | ± 0.35 | ± 0.29 | ± 0.73 | ± 8.26 | ± 209. | ± 61   | ± 23.6 | ± 0.31 |

Footnote: Rsq_adjusted represented a parameter to predict the fitting effect with the actual value, same as adjustment $R^2$; HL_Lambda_z represented elimination phase half-life; $T_{\text{max}}$ represented time to peak; $C_{\text{max}}$ represented peak concentration; $U_{\text{all}}$ represented AUC spanned from the beginning of administration to the last point; $U_{\text{INF}_{\text{obs}}}$ represented AUC spanned from the beginning of administration to the infinite time by extrapolation; $z_{\text{F}_{\text{obs}}}$ represented apparent distribution volume; $Cl_{\text{F}_{\text{obs}}}$ represented clearance rate; $MRT_{\text{last}}$ represented average residence time. Compared with the normal group, * $P < 0.05$; ** $P < 0.01$.

**Figures**

![Chemical structures of four main components in Naoxintong Capsule.](image)

Figure 1

Chemical structures of four main components in Naoxintong Capsule.
Figure 2

Typical MRM chromatograms of various components in rat plasma.
Figure 3

Blood concentration-time curves of caffeic acid, ferulic acid, menthol and tanshinone IIA in normal and acute blood stasis model rats intragastric administration of NXTC.